Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.

The combination of irinotecan and temozolomide was well tolerated, demonstrated some clinical activity across multiple breast cancer subtypes with progressing CNS disease, and offers a reasonable option for patients who are not candidates for further radiation or clinical trials.